Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA)

C. Barinka, J. Ptacek, A. Richter, Z. Novakova, V. Morath, A. Skerra,

. 2016 ; 29 (3) : 105-15. [pub] 20160121

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Although prostate carcinoma (PCa) is by far the most commonly diagnosed neoplasia in men, corresponding diagnostic and therapeutic modalities have limited efficacy at present. Anticalins comprise a novel class of binding proteins based on a non-immunoglobulin scaffold that can be engineered to specifically address molecular targets of interest. Here we report the selection and characterization of Anticalins that recognize human prostate-specific membrane antigen (PSMA), a membrane-tethered metallopeptidase constituting a disease-related target for imaging and therapy of PCa as well as solid malignancies in general. We used a randomized lipocalin library based on the human lipocalin 2 (Lcn2) scaffold together with phage display and ELISA screening to select PSMA-specific variants. Five Anticalin candidates from the original panning were expressed in Escherichia coli as soluble monomeric proteins, revealing affinities toward PSMA down to the low nanomolar range. Binding characteristics of the most promising candidate were further improved via affinity maturation by applying error-prone PCR followed by selection via phage display as well as bacterial surface display under more stringent conditions. In BIAcore measurements, the dissociation constant of the best Anticalin was determined as ∼500 pM, with a substantially improved dissociation rate compared with the first-generation candidate. Finally, immunofluorescence microscopy revealed specific staining of PSMA-positive tumor cell lines while flow cytometric analysis confirmed the ability of the selected Anticalins to detect PSMA on live cells. Taken together, Anticalins resulting from this study offer a viable alternative to antibody-based PSMA binders for biomedical applications, including in vivo imaging of PCa or neovasculature of solid tumors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000587
003      
CZ-PrNML
005      
20170112114346.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/protein/gzv065 $2 doi
024    7_
$a 10.1093/protein/gzv065 $2 doi
035    __
$a (PubMed)26802163
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Barinka, Cyril $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prumyslova 595, 25242 Vestec, Czech Republic cyril.barinka@ibt.cas.cz skerra@tum.de.
245    10
$a Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA) / $c C. Barinka, J. Ptacek, A. Richter, Z. Novakova, V. Morath, A. Skerra,
520    9_
$a Although prostate carcinoma (PCa) is by far the most commonly diagnosed neoplasia in men, corresponding diagnostic and therapeutic modalities have limited efficacy at present. Anticalins comprise a novel class of binding proteins based on a non-immunoglobulin scaffold that can be engineered to specifically address molecular targets of interest. Here we report the selection and characterization of Anticalins that recognize human prostate-specific membrane antigen (PSMA), a membrane-tethered metallopeptidase constituting a disease-related target for imaging and therapy of PCa as well as solid malignancies in general. We used a randomized lipocalin library based on the human lipocalin 2 (Lcn2) scaffold together with phage display and ELISA screening to select PSMA-specific variants. Five Anticalin candidates from the original panning were expressed in Escherichia coli as soluble monomeric proteins, revealing affinities toward PSMA down to the low nanomolar range. Binding characteristics of the most promising candidate were further improved via affinity maturation by applying error-prone PCR followed by selection via phage display as well as bacterial surface display under more stringent conditions. In BIAcore measurements, the dissociation constant of the best Anticalin was determined as ∼500 pM, with a substantially improved dissociation rate compared with the first-generation candidate. Finally, immunofluorescence microscopy revealed specific staining of PSMA-positive tumor cell lines while flow cytometric analysis confirmed the ability of the selected Anticalins to detect PSMA on live cells. Taken together, Anticalins resulting from this study offer a viable alternative to antibody-based PSMA binders for biomedical applications, including in vivo imaging of PCa or neovasculature of solid tumors.
650    _2
$a sekvence aminokyselin $7 D000595
650    _2
$a antigeny povrchové $x chemie $x metabolismus $7 D000954
650    _2
$a ELISA $7 D004797
650    _2
$a glutamátkarboxypeptidasa II $x chemie $x metabolismus $7 D043425
650    _2
$a lidé $7 D006801
650    _2
$a lipokaliny $x genetika $x metabolismus $7 D054834
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární sekvence - údaje $7 D008969
650    _2
$a mutace $7 D009154
650    12
$a proteinové inženýrství $7 D015202
650    _2
$a terciární struktura proteinů $7 D017434
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ptacek, Jakub $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prumyslova 595, 25242 Vestec, Czech Republic Department of Biochemistry, Faculty of Natural Science, Charles University, Albertov 6, Prague 2, Czech Republic.
700    1_
$a Richter, Antonia $u Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, 85354 Freising (Weihenstephan), Germany.
700    1_
$a Novakova, Zora $u Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prumyslova 595, 25242 Vestec, Czech Republic.
700    1_
$a Morath, Volker $u Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, 85354 Freising (Weihenstephan), Germany.
700    1_
$a Skerra, Arne $u Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, 85354 Freising (Weihenstephan), Germany cyril.barinka@ibt.cas.cz skerra@tum.de.
773    0_
$w MED00008154 $t Protein engineering, design & selection PEDS $x 1741-0134 $g Roč. 29, č. 3 (2016), s. 105-15
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26802163 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170112114445 $b ABA008
999    __
$a ok $b bmc $g 1179727 $s 961154
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 29 $c 3 $d 105-15 $e 20160121 $i 1741-0134 $m Protein engineering, design & selection $n Protein Eng Des Sel $x MED00008154
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...